CD274 and cancer: Immune checkpoint inhibitors (ICIs), which are mainly comprised of anti-programmed cell death (ligand)-1 (PD-1/PD-L1) and anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) drugs, have revolutionized the therapeutic landscape for many advanced cancers (1–4).